Antibiotic Prophylaxis: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
Line 62: | Line 62: | ||
|'''Percutaneous renal surgery''' | |'''Percutaneous renal surgery''' | ||
|'''1st/2nd generation cephalosporin OR''' | |'''1st/2nd generation cephalosporin OR''' | ||
'''Aminoglycoside and clindamycin OR''' | |||
'''Aminoglycoside and metronidazole OR''' | '''Aminoglycoside and metronidazole OR''' | ||
'''Aztreonam and metronidazole OR''' | '''Aztreonam and metronidazole OR''' | ||
'''Aztreonam and clindamycin''' | '''Aztreonam and clindamycin''' | ||
Line 73: | Line 73: | ||
|- | |- | ||
|'''Ureteroscopy''' | |'''Ureteroscopy''' | ||
|''' | |'''1st/2nd generation cephalosporin OR''' | ||
''' | '''TMP-SMX''' | ||
|'''Aminoglycoside +/- Ampicillin OR''' | |'''Aminoglycoside +/- Ampicillin OR''' | ||
'''Aztreonam +/- Ampicillin OR''' | '''Aztreonam +/- Ampicillin OR''' | ||
Line 87: | Line 88: | ||
|- | |- | ||
|'''Open, laparoscopic, or robotic surgery involving controlled entry into urinary tract''' | |'''Open, laparoscopic, or robotic surgery involving controlled entry into urinary tract''' | ||
|'''Cefazolin | |'''Cefazolin OR''' | ||
'''TMP-SMX''' | |||
|'''Ampicillin/Sublactam OR''' | |'''Ampicillin/Sublactam OR''' | ||
'''Aminoglycoside and metronidazole OR''' | '''Aminoglycoside and metronidazole OR''' | ||
Line 99: | Line 101: | ||
|- | |- | ||
|'''Implanted prosthetic devices''' | |'''Implanted prosthetic devices''' | ||
|'''Aminoglycoside and 1st/2nd gen cephalosporin OR''' | |'''Aminoglycoside and 1st/2nd gen cephalosporin OR''' | ||
'''Aminoglycoside and Vancomycin OR''' | |||
'''Aztreonam and 1st/2nd generation cephalosporin OR''' | '''Aztreonam and 1st/2nd generation cephalosporin OR''' | ||
'''Aztreonam and Vancomycin''' | '''Aztreonam and Vancomycin''' |
Revision as of 07:25, 15 March 2024
- See Original AUA Guidelines on Antibiotic Prophylaxis
- See Original CUA Guidelines on Antibiotic Prophylaxis
- See CUA Guideline Notes
Surgical Wound Classification
- Clean: uninfected wound without inflammation or entry into the genital, urinary, or alimentary tract
- Clean-contaminated: uninfected wound with controlled entry into the genital, urinary, or alimentary tract
- Contaminated: uninfected wound with major break in sterile technique (gross spillage from gastrointestinal tract or non-purulent inflammation)
- Dirty: wound with preexisting clinical infection or perforated viscera
Risk Factors for Post-Operative Infection
Host Factors (10)
- Advanced age
- Anatomic anomalies
- Poor nutritional status
- Smoking
- Chronic corticosteroid use
- Immunodeficiency
- Chronic indwelling hardware
- Infected endogenous/exogenous material
- Distant co-existent infection
- Prolonged hospitalization
Recommended Prophylaxis
Procedure | Antibiotic | Alternative | Duration |
---|---|---|---|
Cystoscopy with minor manipulation | If risk-factors
TMP-SMX OR Amoxicillin/Clavulanate |
1st/2nd generation cephalosporin OR
Aminoglycoside +/- Ampicillin OR Aztreonam +/- Ampicillin |
Single dose |
Transurethral cases with resection | Cefazolin OR
TMP-SMX |
Amoxicillin/Clavulanate OR
Aminoglycoside +/- Ampicillin OR Aztreonam +/- Ampicillin |
Single dose |
Transrectal prostate biopsy | Fluoroquinolone OR
1st/2nd generation cephalosporin +/- aminoglycoside OR 3rd generation cephalosporin |
Aztreonam
May need infectious disease consultation |
Single dose |
Percutaneous renal surgery | 1st/2nd generation cephalosporin OR
Aminoglycoside and clindamycin OR Aminoglycoside and metronidazole OR Aztreonam and metronidazole OR Aztreonam and clindamycin |
Ampicillin/sublactan | ≤24 hours |
Ureteroscopy | 1st/2nd generation cephalosporin OR
TMP-SMX |
Aminoglycoside +/- Ampicillin OR
Aztreonam +/- Ampicillin OR Amoxicillin/Clavulanate |
Single dose |
Open, laparoscopic, or robotic surgery without entry into urinary tract | Cefazolin | Clindamycin | Single dose |
Open, laparoscopic, or robotic surgery involving controlled entry into urinary tract | Cefazolin OR
TMP-SMX |
Ampicillin/Sublactam OR
Aminoglycoside and metronidazole OR Aztreonam and metronidazole OR Aminoglycoside and clindamycin OR Aztreonam and Clindamycin |
Single dose |
Implanted prosthetic devices | Aminoglycoside and 1st/2nd gen cephalosporin OR
Aminoglycoside and Vancomycin OR Aztreonam and 1st/2nd generation cephalosporin OR Aztreonam and Vancomycin |
Aminopenicillin OR
B-lactamase inhibitor (including ampicillin/sublactan, ticarcillin, tazobactam) |
≤24 hours |
Typical doses§§§§
- TMP/SMX: 800 mg of sulfamethoxazole and 160 mg of trimethorprim PO x 1 dose
- 1st generation cephalosporin: cefazolin 2gm IV x 1 dose
- 3rd generation cephalosporin: cetriaxone 2g IV x 1 dose
- Clindamycin 600mg IV x 1 dose
- Fluoroquinolone: levofloxacin 500mg PO x 1 dose OR ciprofloxacin 500 mg PO x 1 dose
- Aminoglycoside: gentamicin 2mg/kg IV x 1 dose
- Vancomycin 1mg IV x 1 dose
- Metronidazole 500mg IV x 1 dose
- Intraoperative redosing if required
- Cefazolin 2gm IV q4h
- Clindamycin 600mg IV q8h
- Gentamicin 1mg/kg q8h
- Metronidazole 500mg IV q6h
Urinary Catheter Removal
- Does not significantly reduce risk of UTIs in patients undergoing radical prostatectomy or TURP
- 2021 Systematic Review and Meta-Analysis
- 8 randomized trials evaluating antibiotic prophylaxis for UTIs after extraction of a temporary (≤14 days) urinary catheter.
- 2 trials were laparoscopic radical prostatectomy patients
- 1 trial was TURP patients
- Results
- Only 2 studies showed that antibiotic prophylaxis can significantly reduce the consequent UTIs after extraction of urinary catheters while 6 did not.
- None of the 3 urological trials found a significant benefit of antibiotic prophylaxis
- 2 trials that found benefit were in patients undergoing abdominal surgery or women on medical and surgical wards with bacteriuria
- Overall, antibiotic prophylaxis was associated with reduced UTIs (RR, 0.47, 95% confidence interval [CI] 0.28-0.72, P< .01, I2 = 31%).
- Subgroup analysis suggested that patients who could get more benefit from antibiotic prophylaxis included
- Are > 60
- Received Trimethoprim/sulfamethoxazole (TMP/SMX
- indwelling catheters > 5 days
- Only 2 studies showed that antibiotic prophylaxis can significantly reduce the consequent UTIs after extraction of urinary catheters while 6 did not.
- Liu, Linhu, et al. "Antibiotic prophylaxis after extraction of urinary catheter prevents urinary tract infections: A systematic review and meta-analysis." American Journal of Infection Control 49.2 (2021): 247-254.
- 8 randomized trials evaluating antibiotic prophylaxis for UTIs after extraction of a temporary (≤14 days) urinary catheter.
- 2021 Systematic Review and Meta-Analysis
Special considerations
Risk of endocarditis
- The risk of infectious endocarditis (IE) after urologic procedures is low.
- Enterococcus faecaelis is the pathogen most likely responsible for IE following a genitorurinary tract bacteremia
- The current recommendation is that the use of prophylactic antibiotics solely to prevent IE is not recommended
- Previous guidelines from the American Heart Association had recommended routine prophylaxis
- The guidelines do state that for patients with certain concomitant conditions (prosthetic cardiac valve, previous IE, congenital heart disease, cardiac transplantation) AND an active infection or colonization who are to undergo GU tract manipulation, including elective cystoscopy, antibiotic therapy to sterilize the urine may be reasonable (Class IIb evidence).
- Amoxicillin or ampicillin is suggested as a first-line agent for enterococci, vancomycin for penicillin allergy
Indwelling orthopedic hardware
- In general, antibiotic prophylaxis for urologic patients with total joint replacements, pins, plates, or screws is not indicated.
- Prophylaxis is advised for individuals at higher risk of seeding a prosthetic joint, including those with recently inserted implants (within 2 years) and/or host risk factors as delineated earlier
Questions
Answers
References
- Wein AJ, Kavoussi LR, Partin AW, Peters CA (eds): CAMPBELL-WALSH UROLOGY, ed 11. Philadelphia, Elsevier, 2015, vol 2, chap 12
- Lightner, Deborah J., et al. "Best practice statement on urologic procedures and antimicrobial prophylaxis." The Journal of Urology 203.2 (2020): 351-356.